Terms: = Lymphoma AND TP53, TRP53, 7157, ENSG00000141510, P04637, LFS1, P53 AND Prognosis
643 results:
1. Genomic landscape and distinct molecular subtypes of primary testicular lymphoma.
Zhang W; Yang P; Yang Y; Liu S; Xu Y; Wu C; Wang J; Liu C; Liu H; Li S; Huang W; Jing H
J Transl Med; 2024 May; 22(1):414. PubMed ID: 38693538
[TBL] [Abstract] [Full Text] [Related]
2. p53-Armed Oncolytic Virotherapy Improves Radiosensitivity in Soft-Tissue Sarcoma by Suppressing BCL-xL Expression.
Komatsubara T; Tazawa H; Hasei J; Omori T; Sugiu K; Mochizuki Y; Demiya K; Yoshida A; Fujiwara T; Kunisada T; Urata Y; Kagawa S; Ozaki T; Fujiwara T
Acta Med Okayama; 2024 Apr; 78(2):151-161. PubMed ID: 38688833
[TBL] [Abstract] [Full Text] [Related]
3. The tp53-activated E3 ligase RNF144B is a tumour suppressor that prevents genomic instability.
Abad E; Sandoz J; Romero G; Zadra I; Urgel-Solas J; Borredat P; Kourtis S; Ortet L; Martínez CM; Weghorn D; Sdelci S; Janic A
J Exp Clin Cancer Res; 2024 Apr; 43(1):127. PubMed ID: 38685100
[TBL] [Abstract] [Full Text] [Related]
4. XPO1 blockade with KPT-330 promotes apoptosis in cutaneous T-cell lymphoma by activating the p53-p21 and p27 pathways.
Chakravarti N; Boles A; Burzinski R; Sindaco P; Isabelle C; McConnell K; Mishra A; Porcu P
Sci Rep; 2024 Apr; 14(1):9305. PubMed ID: 38653804
[TBL] [Abstract] [Full Text] [Related]
5. Mutation landscape in Chinese nodal diffuse large B-cell lymphoma by targeted next generation sequencing and their relationship with clinicopathological characteristics.
Cao B; Sun C; Bi R; Liu Z; Jia Y; Cui W; Sun M; Yu B; Li X; Zhou X
BMC Med Genomics; 2024 Apr; 17(1):84. PubMed ID: 38609996
[TBL] [Abstract] [Full Text] [Related]
6. Full-spectral genome analysis of natural killer/T cell lymphoma highlights impacts of genome instability in driving its progression.
Chen Z; Huang H; Hong H; Huang H; Weng H; Yu L; Xiao J; Wang Z; Fang X; Yao Y; Yue JX; Lin T
Genome Med; 2024 Apr; 16(1):48. PubMed ID: 38566223
[TBL] [Abstract] [Full Text] [Related]
7. A multicenter study of venetoclax-based treatment for patients with Richter transformation of chronic lymphocytic leukemia.
Hampel PJ; Swaminathan M; Rogers KA; Parry EM; Burger JA; Davids MS; Ding W; Ferrajoli A; Hyak JM; Jain N; Kenderian SS; Wang Y; Wierda WG; Woyach JA; Parikh SA; Thompson PA
Blood Adv; 2024 May; 8(10):2342-2350. PubMed ID: 38537065
[TBL] [Abstract] [Full Text] [Related]
8. Matching-Adjusted Indirect Comparison of Brexucabtagene Autoleucel (ZUMA-2) and Pirtobrutinib (BRUIN) in Patients with Relapsed/Refractory Mantle Cell lymphoma Previously Treated with a Covalent Bruton Tyrosine Kinase Inhibitor.
Salles G; Chen JMH; Zhang I; Kerbauy F; Wu JJ; Wade SW; Nunes A; Feng C; Kloos I; Peng W; Snider JT; Maciel D; Chan K; Keeping S; Shah B
Adv Ther; 2024 May; 41(5):1938-1952. PubMed ID: 38494543
[TBL] [Abstract] [Full Text] [Related]
9. Hairy cell leukemia 2024: Update on diagnosis, risk-stratification, and treatment-Annual updates in hematological malignancies.
Troussard X; Maître E; Paillassa J
Am J Hematol; 2024 Apr; 99(4):679-696. PubMed ID: 38440808
[TBL] [Abstract] [Full Text] [Related]
10. Pan-cancer analysis of RNA 5-methylcytosine reader (ALYREF).
Ye X; Tuo Z; Chen K; Wu R; Wang J; Yu Q; Ye L; Miyamoto A; Yoo KH; Zhang C; Wei W; Li D; Feng D
Oncol Res; 2024; 32(3):503-515. PubMed ID: 38361753
[TBL] [Abstract] [Full Text] [Related]
11. Biomarker analysis of the ASPEN study comparing zanubrutinib with ibrutinib for patients with Waldenström macroglobulinemia.
Tam CS; Opat S; D'Sa S; Jurczak W; Lee HP; Cull G; Owen RG; Marlton P; Wahlin BE; García-Sanz R; McCarthy H; Mulligan S; Tedeschi A; Castillo JJ; Czyż J; Fernández De Larrea C; Belada D; Libby E; Matous J; Motta M; Siddiqi T; Tani M; Trněný M; Minnema MC; Buske C; Leblond V; Treon SP; Trotman J; Wu B; Yu Y; Shen Z; Chan WY; Schneider J; Allewelt H; Cohen A; Dimopoulos MA
Blood Adv; 2024 Apr; 8(7):1639-1650. PubMed ID: 38315878
[TBL] [Abstract] [Full Text] [Related]
12. Predictive and prognostic molecular biomarkers in lymphomas.
Iorgulescu JB; Medeiros LJ; Patel KP
Pathology; 2024 Mar; 56(2):239-258. PubMed ID: 38216400
[TBL] [Abstract] [Full Text] [Related]
13. 1q21+ is associated with poor prognosis in newly diagnosed multiple myeloma patients with extramedullary disease: a retrospective study.
Gao S; Dong F; Yang P; Chen Y; Wang Y; Wang J; Shi Y; Jing H
Ann Hematol; 2024 Jun; 103(6):1979-1987. PubMed ID: 38206369
[TBL] [Abstract] [Full Text] [Related]
14. Selectively targeting BCL6 using a small molecule inhibitor is a potential therapeutic strategy for ovarian cancer.
Wu M; Xie J; Xing Y; Zhang L; Chen H; Tang B; Zhou M; Lv S; Huang D; Jian S; Zhou C; Liu M; Guo W; Chen Y; Yi Z
Int J Biol Sci; 2024; 20(2):486-501. PubMed ID: 38169532
[TBL] [Abstract] [Full Text] [Related]
15. Anlotinib suppresses the DNA damage response by disrupting SETD1A and inducing p53-dependent apoptosis in Transformed Follicular lymphoma.
Zhuang X; Yao J; Li X; Jiang Y; Zhong M; Tan J; Zhou H; Li G; Zha J; Xu B
Int J Med Sci; 2024; 21(1):70-79. PubMed ID: 38164353
[No Abstract] [Full Text] [Related]
16. Comprehensive analysis of the prognostic implication and immune infiltration of CISD2 in diffuse large B-cell lymphoma.
Zhang C; Lin Q; Li C; Qiu Y; Chen J; Zhu X
Front Immunol; 2023; 14():1277695. PubMed ID: 38155967
[TBL] [Abstract] [Full Text] [Related]
17. DNA Copy Number Alterations and Copy Neutral Loss of Heterozygosity in Adult Ph-Negative Acute B-Lymphoblastic Leukemia: Focus on the Genes Involved.
Risinskaya N; Gladysheva M; Abdulpatakhov A; Chabaeva Y; Surimova V; Aleshina O; Yushkova A; Dubova O; Kapranov N; Galtseva I; Kulikov S; Obukhova T; Sudarikov A; Parovichnikova E
Int J Mol Sci; 2023 Dec; 24(24):. PubMed ID: 38139431
[TBL] [Abstract] [Full Text] [Related]
18. Genetic Characterization of Primary Mediastinal B-Cell lymphoma: Pathogenesis and Patient Outcomes.
Noerenberg D; Briest F; Hennch C; Yoshida K; Hablesreiter R; Takeuchi Y; Ueno H; Staiger AM; Ziepert M; Asmar F; Locher BN; Toth E; Weber T; Amini RM; Klapper W; Bouzani M; Poeschel V; Rosenwald A; Held G; Campo E; Ishaque N; Stamatopoulos K; Kanellis G; Anagnostopoulos I; Bullinger L; Goldschmidt N; Zinzani PL; Bödör C; Rosenquist R; Vassilakopoulos TP; Ott G; Ogawa S; Damm F
J Clin Oncol; 2024 Feb; 42(4):452-466. PubMed ID: 38055913
[TBL] [Abstract] [Full Text] [Related]
19. [Analysis of the feasibility and prognostic value of circulating tumor DNA monitoring in detecting gene mutations in patients with diffuse large B-cell lymphoma receiving chimeric antigen receptor T-cell therapy].
Zhou LH; Feng YQ; Hu YX; Huang H
Zhonghua Xue Ye Xue Za Zhi; 2023 Oct; 44(10):805-812. PubMed ID: 38049331
[No Abstract] [Full Text] [Related]
20. Establishment of ganglioside GD2-expressing extranodal NK/T-cell lymphoma cell line with scRNA-seq analysis.
Sato S; Ishii M; Tachibana K; Furukawa Y; Toyota T; Kinoshita S; Azusawa Y; Ando J; Ando M
Exp Hematol; 2024 Feb; 130():104132. PubMed ID: 38029851
[TBL] [Abstract] [Full Text] [Related]
[Next]
